Antibody therapy is able to reduce harmful cholesterol by 50%.

An American research study has revealed a hospital Mount Sinai In New York on the success of a drug evinacumab Experimental reduction of low-density lipoprotein cholesterol, or so-called “bad” cholesterol, by 50% in patients with severe hypercholesterolemia, whose condition is resistant to standard treatments, according to a newspaper. TIME NOW NEWS .

The results of the study were presented in scientific sessions of the American Heart Association and simultaneously published in a journal New England Journal of Medicine.

Evinacumab It is a fully human monoclonal antibody that works through a different mechanism than current medications to bring dangerously high cholesterol levels to normal when combined with lipid-lowering therapies tolerated by people with familial hypercholesterolemia, a common genetic condition that is difficult to treat..

Chief Investigator Robert Rosenson, Professor of Cardiology and Director of Cardiovascular Disorders at the School of Medicine, said. Mount Sinaik This drug is a fully human monoclonal antibody that lowers harmful cholesterol.

The second phase of the multicenter study involved 272 patients with primary hypercholesterolemia, including most of them diagnosed with familial hypercholesterolemia, an inherited form of hypercholesterolemia often caused by mutations in the receptor gene. LDLThe research team found that subcutaneous administration of the antibody component at a dose of 450 mg per week reduced LDL cholesterol by 56% and 52.9% with an average of 300 mg per week compared to the placebo group..

With giving evinacumab On monthly intravenous administration at 15 mg / kg, the reduction in LDL cholesterol was 50.5% compared to the placebo group. All patients treated with ivinacumab were on background lipid-lowering treatment.